Supplemental material
Leukemia & Lymphoma
Volume 64, 2023 - Issue 12
Original Articles
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models
Natsumi KawasakiProduct Research Department, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan
https://orcid.org/0000-0003-0422-3853View further author information
https://orcid.org/0000-0003-0422-3853View further author information, Mayu TomitaProduct Research Department, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japanhttps://orcid.org/0000-0003-4348-6840View further author information
https://orcid.org/0000-0003-4348-6840View further author information, Yoriko Yamashita-KashimaProduct Research Department, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japanhttps://orcid.org/0000-0002-1157-649XView further author information
https://orcid.org/0000-0002-1157-649XView further author information, & Shigeki YoshiuraProduct Research Department, Chugai Pharmaceutical Co., Ltd., Kanagawa, JapanCorrespondence[email protected]
https://orcid.org/0000-0002-2401-148XView further author information
https://orcid.org/0000-0002-2401-148XView further author information